| Literature DB >> 35674792 |
Kathrine F Vandraas1, Kristin V Reinertsen2, Cecilie E Kiserud2, Synne K Bøhn2, Hanne C Lie2,3.
Abstract
BACKGROUND: Poor health literacy may hamper health management and long-term outcomes in breast cancer survivorship. Knowledge of factors associated with poor health literacy is needed to identify survivors in need of additional support and to improve the quality of health care, but is currently scant. Here, we explore health literacy and associated factors in a nationwide sample of long-term survivors of breast cancer.Entities:
Keywords: Breast cancer survivorship; Fear of cancer recurrence; Health literacy; Neuroticism
Mesh:
Year: 2022 PMID: 35674792 PMCID: PMC9385742 DOI: 10.1007/s00520-022-07183-3
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.359
Description of study sample (n=1355) for categorical (n (%)) and continuous (mean, SD and median, range) variables
| Categorical variables | ||
|---|---|---|
| Socioeconomic variables | ||
Education ≤ 12 y Education >12 y | 647 (47.7) 691 (51.0) | |
- ≤4 years higher education - >4 years higher education | 290 (21.4) 401 (29.6) | |
| High household incomea | 923 (68.1) | |
| Living with a partner or children | 1079 (79.6) | |
| Employmentb | 1035 (76.4) | |
| Clinical variables | ||
| Receptor expression | ||
| - Hormone receptor positive | 1153 (85.1) | |
| - HER-2 positive | 248 (18.3) | |
| Triple negative | 116 (8.6) | |
| Stage (TNM)c | ||
I II III | 606 (44.7) 486 (35.9) 108 (8.0) | |
| Surgeryd | ||
- Mastectomy - Breast-conserving therapy | 559 (41.3) 788 (58.2) | |
| Chemotherapy, all regimens | 926 (68.3) | |
| Radiotherapy, all regimens | 1087 (80.2) | |
| Endocrine therapy, all regimens | 881 (65.0) | |
| Herceptin | 242 (17.9) | |
| Physical health | ||
| Comorbidity | ||
| - 1–2 conditions | 731 (53.9) | |
| - >2 conditions | 326 (24.1) | |
| Neuropathy (SCIN) | 277 (20.4) | |
| Sleep problems (HUNT)e | 59.2 (43.7) | |
| Continous variables | ||
| Age at survey (years) | 59.9 (8.7) | 60.0 (30–74) |
| Age at diagnosis (years) | 51.9 (8.6) | 52.0 (21–65) |
| Time since diagnosis (years) | 8.0 (0.7) | 8.02 (7–9) |
| Neuroticism (Eysenck Personality questionnaire)f | 2.17 (1.9) | 2.0 (0–6) |
| Cognitive function (EORTC QLQ-C30)g | 74.3 (24.9) | 83.3 (0–100) |
| Arm symptoms (EORTC QLQ BR-23)f | 20.7 (24.6) | 11.1 (0–100) |
| Breast symptoms (EORTC QLQ BR-23)f | 16.2 (19.3) | 8.3 (0–100) |
| Pain (EORTC QLQ-C30)f | 28.1 (29.4) | 16.7 (0–100) |
| Depressive symptoms (PHQ-9)f | 5.9 (4.5) | 5.0 (0–27) |
| Anxiety symptoms (GAD-7)f | 3.8 (3.6) | 3.0 (0–21) |
| Fear of cancer recurrence (CARQ)f | 11.7 (8.7) | 9.0 (0–40) |
| Fatigue (Chalder’s fatigue questionnaire)f | 14.8 (5.8) | 13.0 (0–33) |
Abbreviations: HER-2, human epidermal growth receptor-2; SCIN, scale for chemotherapy-induced long-term neurotoxicity; HUNT, Nord-Trøndelag Health Study; EORTC QLQ, European Organization for Research and Treatment of Cancer quality of life questionnaire; PHQ-9, The Patient Health Questionnaire-9; GAD-7, General Anxiety Disorder 7-item scale; CARQ, Concern About Recurrence Questionnaire. a≥ 500000 NOK/year equal to 48000€/year. bEmployment = paid work (full time, part time, on sick leave), self-employed and freelance. cn= 1200 due to missing values for 11.4%. dn=1347 due to missing values for 0.6%. eExperiencing one or more of the following at least 3 times per week: difficulties falling asleep at night and/or waking up too early without being able to go back to sleep. fIncreasing score=increasing symptoms. gIncreasing score = increasing function
Frequencies of responses categorized from very difficult to very easy for each item of The European Health Literacy Survey Questionnaire-12 (range 12–48), categorized health literacy levels from inadequate to advanced, and health literacy sum scores before and after imputation
| Very difficult | Difficult | Easy | Very easy | Don’t know | ||
|---|---|---|---|---|---|---|
| On a scale from very difficult to very easy, how easy would you say it is to: | ||||||
| 1324 (97.7) | 21 (1.5) | 198 (14.6) | 744 (54.9) | 214 (15.8) | 147 (10.8) | |
| 1311 (96.8) | 25 (1.8) | 287 (21.2) | 664 (49.0) | 200 (14.8) | 135 (10.0) | |
| 1247 (92.0) | 53 (3.9) | 504 (37.2) | 455 (33.6) | 99 (7.3) | 136 (10.0) | |
| 1323 (97.6) | 3 (0.2) | 49 (3.6) | 742 (54.8) | 500 (36.9) | 29 (2.1) | |
| 1319 (97.3) | 26 (1.9) | 299 (22.1) | 592 (43.7) | 162 (12.0) | 240 (17.7) | |
| 1331 (98.2) | 2 (0.1) | 32 (2.4) | 635 (46.9) | 636 (46.9) | 26 (1.9) | |
| 1303 (96.2) | 47 (3.5) | 431 (31.8) | 535 (39.5) | 157 (11.6) | 133 (9.8) | |
| 1308 (96.5) | 49 (3.6) | 333 (24.6) | 522 (38.5) | 157 (11.6) | 247 (18.2) | |
| 1322 (97.6) | 8 (0.6) | 69 (5.1) | 748 (55.2) | 478 (35.3) | 19 (1.4) | |
| 1320 (97.4) | 14 (1.0) | 221 (16.3) | 703 (51.9) | 347 (25.6) | 35 (2.6) | |
| 1320 (97.4) | 7 (0.5) | 135 (10.0) | 742 (54.8) | 412 (30.4) | 24 (1.8) | |
| 1326 (97.9) | 23 (1.7) | 324 (23.9) | 682 (50.3) | 275 (20.3) | 22 (1.6) | |
| Health literacy, categorized | ||||||
| - Inadequate (12–26 points) | 31 (2.3) | |||||
| - Marginal (27–32 points) | 231 (17.0) | |||||
| - Intermediate (33–38 points) | 528 (39.0) | |||||
| - Advanced (39–48 points) | 328 (24.2) | |||||
| Total | 1118 (82.5)a | |||||
| Health literacy sum score, prior to imputation (range 12–48) | 36.4 (5.5) | |||||
| Health literacy sum score, after imputation (range 12–48) | 36.2 (5.4) | |||||
aMissing values (non-responders and “don’t know” responses): 237 (17.5%)
Univariate linear regression analysis with health literacy sum score as dependent variable
| Unstandardized coefficient | Standardized coefficient | Sig.a | 95% CIb for | ||
|---|---|---|---|---|---|
| Lower bound | Upper bound | ||||
| Educationc | 1.09 | 0.08 | 0.22 | 1.96 | |
| >4 y. higher education | 2.43 | 0.21 | 1.67 | 3.20 | |
| Household incomec | 2.21 | 0.19 | 1.47 | 2.94 | |
| Living with partner/childrend | −0.34 | −0.03 | 0.44 | −1.21 | 0.53 |
| Age at survey | −0.07 | −0.11 | −0.11 | −0.03 | |
| Employmentd | −1.16 | −0.09 | −1.99 | −0.33 | |
| Age at diagnosis | −0.07 | −0.11 | −0.11 | −0.03 | |
| Hormone receptor positivityd | −1.21 | −0.08 | −2.17 | −0.24 | |
| TNM stage 2 vs 1 | −0.59 | −0.05 | 0.11 | −1.32 | 0.14 |
| TNM stage 3 vs 1 | −0.40 | −0.02 | 0.54 | −1.65 | 0.86 |
| TNBCd | 0.80 | 0.04 | 0.20 | −0.41 | 2.02 |
| Surgeryd | −0.36 | −0.03 | 0.30 | −1.05 | 0.33 |
| Chemotherapyd | 0.49 | 0.04 | 0.20 | −0.26 | 1.24 |
| Radiotherapyd | −0.43 | −0.03 | 0.32 | −1.28 | 0.41 |
| Endocrine therapyd | −0.22 | −0.02 | 0.56 | −0.96 | 0.52 |
| Herceptind | 0.59 | 0.04 | 0.20 | −0.31 | 1.49 |
| 1–2 comorbid conditionsd | −1.00 | −0.09 | −1.86 | −0.14 | |
| >2 comorbid conditionsd | −1.48 | −0.12 | −2.47 | −0.48 | |
| Paine | −0.02 | −0.11 | −0.03 | −0.01 | |
| Cognitiv functionf | 0.03 | 0.16 | 0.02 | 0.05 | |
| Breast symptomse | −0.04 | −0.13 | −0.06 | −0.02 | |
| Arm symptomse | −0.03 | −0.14 | −0.04 | −0.02 | |
| Neuropathyc | −0.87 | −0.07 | −1.69 | −0.04 | |
| Sleep problemsd | −0.67 | −0.06 | 0.06 | −1.37 | 0.03 |
| Fatiguee | −0.11 | −0.12 | −0.17 | −0.05 | |
| Depressive symptomse | −0.21 | −0.18 | −0.28 | −0.13 | |
| Anxiety symptomse | −0.32 | −0.21 | −0.41 | −0.22 | |
| Fear of cancer recurrencee | −0.15 | −0.23 | −0.18 | −0.11 | |
| Neuroticisme | −0.67 | −0.24 | −0.85 | −0.50 | |
aSignificance level, bconfidence interval, creference low, dreference not, ehigher score implies worse symptoms, fhigher score implies better function. Bold: Statistically significant (p<.05) associated with HL
Multivariate linear regression analysis with health literacy sum score as dependent variable
| Unstandardized coefficients | SEa | Standardized coefficients | Sig.b | ||
|---|---|---|---|---|---|
| 0.14 | 0.12 | ||||
| Educationc | 0.55 | 0.44 | 0.04 | 0.21 | |
| >4 y. higher education | 1.32 | 0.41 | 0.12 | ||
| Household incomec | 1.11 | 0.40 | 0.10 | ||
| Employmentd | 0.17 | 0.41 | 0.02 | 0.68 | |
| Age at diagnosis | −0.08 | 0.03 | −0.13 | ||
| Hormone receptor positivityd | −0.72 | 0.47 | −0.05 | 0.13 | |
| 1–2 comorbid conditionsd | −0.16 | 0.44 | −0.02 | 0.72 | |
| >2 comorbid conditionsd | 0.17 | 0.56 | 0.01 | 0.76 | |
| Paine | 0.01 | 0.01 | 0.06 | 0.18 | |
| Cognitiv functionf | 0.02 | 0.01 | 0.08 | 0.08 | |
| Breast symptomse | 0.00 | 0.01 | −0.01 | 0.89 | |
| Arm symptomse | −0.02 | 0.01 | −0.07 | 0.08 | |
| Neuropathyc | 0.06 | 0.44 | 0.00 | 0.90 | |
| Sleep problemsd | 0.44 | 0.37 | 0.04 | 0.24 | |
| Fatiguee | 0.01 | 0.04 | 0.02 | 0.74 | |
| Depressive symptomse | −0.01 | 0.07 | −0.01 | 0.84 | |
| Anxiety symptomse | −0.12 | 0.08 | −0.08 | 0.12 | |
| Fear of cancer recurrencee | −0.08 | 0.02 | −0.13 | ||
| Neuroticisme | −0.27 | 0.13 | −0.10 |
aStandard error, bsignificance level, creference low, dreference not, ehigher score implies worse symptoms, fhigher score implies better function. Bold: Statistically significant (p<.05) associated with HL